Receptos is a biopharmaceutical
company developing therapeutic candidates for the treatment of autoimmune
disease through information-drive discovery including GPCR structure
determination. Receptos products are now
undergoing clinical evaluation in multiple sclerosis and ulcerative colitis.
Other investors include: ARCH Venture Partners, Flagship Ventures, Polaris
Ventures Partners and Venrock.